These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 30918961)
1. Targeted copy number analysis outperforms histologic grading in predicting patient survival for WHO grades II/III IDH-mutant astrocytomas. Cimino PJ; Holland EC Neuro Oncol; 2019 Jun; 21(6):819-821. PubMed ID: 30918961 [No Abstract] [Full Text] [Related]
2. Establishing a prognostic threshold for total copy number variation within adult IDH-mutant grade II/III astrocytomas. Mirchia K; Snuderl M; Galbraith K; Hatanpaa KJ; Walker JM; Richardson TE Acta Neuropathol Commun; 2019 Jul; 7(1):121. PubMed ID: 31349875 [No Abstract] [Full Text] [Related]
3. Rapid progression to glioblastoma in a subset of IDH-mutated astrocytomas: a genome-wide analysis. Richardson TE; Snuderl M; Serrano J; Karajannis MA; Heguy A; Oliver D; Raisanen JM; Maher EA; Pan E; Barnett S; Cai C; Habib AA; Bachoo RM; Hatanpaa KJ J Neurooncol; 2017 May; 133(1):183-192. PubMed ID: 28421459 [TBL] [Abstract][Full Text] [Related]
4. T2-FLAIR Mismatch Sign Predicts DNA Methylation Subclass and CDKN2A/B Status in IDH-Mutant Astrocytomas. Lee MD; Jain R; Galbraith K; Chen A; Lieberman E; Patel SH; Placantonakis DG; Zagzag D; Barbaro M; Guillermo Prieto Eibl MDP; Golfinos JG; Orringer DA; Snuderl M Clin Cancer Res; 2024 Aug; 30(16):3512-3519. PubMed ID: 38829583 [TBL] [Abstract][Full Text] [Related]
5. IDH mutant lower grade (WHO Grades II/III) astrocytomas can be stratified for risk by CDKN2A, CDK4 and PDGFRA copy number alterations. Yang RR; Shi ZF; Zhang ZY; Chan AK; Aibaidula A; Wang WW; Kwan JSH; Poon WS; Chen H; Li WC; Chung NY; Punchhi G; Chu WC; Chan IS; Liu XZ; Mao Y; Li KK; Ng HK Brain Pathol; 2020 May; 30(3):541-553. PubMed ID: 31733156 [TBL] [Abstract][Full Text] [Related]
6. Novel, improved grading system(s) for IDH-mutant astrocytic gliomas. Shirahata M; Ono T; Stichel D; Schrimpf D; Reuss DE; Sahm F; Koelsche C; Wefers A; Reinhardt A; Huang K; Sievers P; Shimizu H; Nanjo H; Kobayashi Y; Miyake Y; Suzuki T; Adachi JI; Mishima K; Sasaki A; Nishikawa R; Bewerunge-Hudler M; Ryzhova M; Absalyamova O; Golanov A; Sinn P; Platten M; Jungk C; Winkler F; Wick A; Hänggi D; Unterberg A; Pfister SM; Jones DTW; van den Bent M; Hegi M; French P; Baumert BG; Stupp R; Gorlia T; Weller M; Capper D; Korshunov A; Herold-Mende C; Wick W; Louis DN; von Deimling A Acta Neuropathol; 2018 Jul; 136(1):153-166. PubMed ID: 29687258 [TBL] [Abstract][Full Text] [Related]
7. Prognostic value of DNA methylation subclassification, aneuploidy, and CDKN2A/B homozygous deletion in predicting clinical outcome of IDH mutant astrocytomas. Galbraith K; Garcia M; Wei S; Chen A; Schroff C; Serrano J; Pacione D; Placantonakis DG; William CM; Faustin A; Zagzag D; Barbaro M; Eibl MDPGP; Shirahata M; Reuss D; Tran QT; Alom Z; von Deimling A; Orr BA; Sulman EP; Golfinos JG; Orringer DA; Jain R; Lieberman E; Feng Y; Snuderl M Neuro Oncol; 2024 Jun; 26(6):1042-1051. PubMed ID: 38243818 [TBL] [Abstract][Full Text] [Related]
8. IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO. Reuss DE; Mamatjan Y; Schrimpf D; Capper D; Hovestadt V; Kratz A; Sahm F; Koelsche C; Korshunov A; Olar A; Hartmann C; Reijneveld JC; Wesseling P; Unterberg A; Platten M; Wick W; Herold-Mende C; Aldape K; von Deimling A Acta Neuropathol; 2015 Jun; 129(6):867-73. PubMed ID: 25962792 [TBL] [Abstract][Full Text] [Related]
9. Mitotic Index Thresholds Do Not Predict Clinical Outcome for IDH-Mutant Astrocytoma. Yoda RA; Marxen T; Longo L; Ene C; Wirsching HG; Keene CD; Holland EC; Cimino PJ J Neuropathol Exp Neurol; 2019 Nov; 78(11):1002-1010. PubMed ID: 31529048 [TBL] [Abstract][Full Text] [Related]
10. Mismatch repair proteins PMS2 and MLH1 can further refine molecular stratification of IDH-mutant lower grade astrocytomas. Yang RR; Li KK; Zhang ZY; Chan AK; Wang WW; Chan DT; Li WC; Liu XZ; Li FC; Chen H; Ng HK; Mao Y; Shi ZF Clin Neurol Neurosurg; 2021 Sep; 208():106882. PubMed ID: 34428613 [TBL] [Abstract][Full Text] [Related]
11. Prognostic stratification for IDH-wild-type lower-grade astrocytoma by Sanger sequencing and copy-number alteration analysis with MLPA. Makino Y; Arakawa Y; Yoshioka E; Shofuda T; Kawauchi T; Terada Y; Tanji M; Kanematsu D; Mineharu Y; Miyamoto S; Kanemura Y Sci Rep; 2021 Jul; 11(1):14408. PubMed ID: 34257410 [TBL] [Abstract][Full Text] [Related]
12. cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas. Brat DJ; Aldape K; Colman H; Figrarella-Branger D; Fuller GN; Giannini C; Holland EC; Jenkins RB; Kleinschmidt-DeMasters B; Komori T; Kros JM; Louis DN; McLean C; Perry A; Reifenberger G; Sarkar C; Stupp R; van den Bent MJ; von Deimling A; Weller M Acta Neuropathol; 2020 Mar; 139(3):603-608. PubMed ID: 31996992 [No Abstract] [Full Text] [Related]
13. Refinement of prognostication for IDH-mutant astrocytomas using DNA methylation-based classification. Kling T; Ferreyra Vega S; Suman M; Dénes A; Lipatnikova A; Lagerström S; Olsson Bontell T; Jakola AS; Carén H Brain Pathol; 2024 Sep; 34(5):e13233. PubMed ID: 38168467 [TBL] [Abstract][Full Text] [Related]
14. Molecular Signatures of Chromosomal Instability Correlate With Copy Number Variation Patterns and Patient Outcome in IDH-Mutant and IDH-Wildtype Astrocytomas. Richardson TE; Sathe AA; Xing C; Mirchia K; Viapiano MS; Snuderl M; Abdullah KG; Hatanpaa KJ; Walker JM J Neuropathol Exp Neurol; 2021 Mar; 80(4):354-365. PubMed ID: 33755138 [TBL] [Abstract][Full Text] [Related]
15. Gain of 12p encompassing CCND2 is associated with gemistocytic histology in IDH mutant astrocytomas. Sahm F; Korshunov A; Schrimpf D; Stichel D; Jones DT; Capper D; Koelsche C; Reuss D; Kratz A; Huang K; Wefers AK; Schick M; Bewerunge-Hudler M; Mittelbronn M; Platten M; Hänggi D; Jeibmann A; Unterberg A; Herold-Mende C; Pfister SM; Brandner S; Wick W; von Deimling A Acta Neuropathol; 2017 Feb; 133(2):325-327. PubMed ID: 28000032 [No Abstract] [Full Text] [Related]
16. Clinical implications of molecular analysis in diffuse glioma stratification. Mizoguchi M; Hata N; Kuga D; Hatae R; Akagi Y; Sangatsuda Y; Fujioka Y; Takigawa K; Funakoshi Y; Suzuki SO; Iwaki T Brain Tumor Pathol; 2021 Jul; 38(3):210-217. PubMed ID: 34268651 [TBL] [Abstract][Full Text] [Related]
17. IDH mutations as an early and consistent marker in low-grade astrocytomas WHO grade II and their consecutive secondary high-grade gliomas. Juratli TA; Kirsch M; Robel K; Soucek S; Geiger K; von Kummer R; Schackert G; Krex D J Neurooncol; 2012 Jul; 108(3):403-10. PubMed ID: 22410704 [TBL] [Abstract][Full Text] [Related]
18. Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities. Reuss DE; Kratz A; Sahm F; Capper D; Schrimpf D; Koelsche C; Hovestadt V; Bewerunge-Hudler M; Jones DT; Schittenhelm J; Mittelbronn M; Rushing E; Simon M; Westphal M; Unterberg A; Platten M; Paulus W; Reifenberger G; Tonn JC; Aldape K; Pfister SM; Korshunov A; Weller M; Herold-Mende C; Wick W; Brandner S; von Deimling A Acta Neuropathol; 2015 Sep; 130(3):407-17. PubMed ID: 26087904 [TBL] [Abstract][Full Text] [Related]